Brooks Laboratories Intrinsic Value
Brooks Laboratories (BROOKS) median intrinsic value is ₹36.03 from 9 valuation models (range ₹22–₹82), vs current price ₹72.07 — -50.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Read BROOKS dividend payout details for the complete payout history and dividend yield track record.
BROOKS Valuation Methods Summary — DCF, Graham Number & P/E
Brooks Laboratories intrinsic value across 9 models vs current price ₹72.07 — upside/downside and value range per method. For current market price and key ratios, visit Brooks Laboratories stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹45.76 | ₹36.61 - ₹54.91 | -36.5% | EPS: ₹2.08, Sector P/E: 22x |
| Book Value Method | asset | ₹82.00 | ₹73.80 - ₹90.20 | +13.8% | Book Value/Share: ₹41.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹58.67 | ₹52.80 - ₹64.54 | -18.6% | Revenue/Share: ₹29.33, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹28.83 | ₹25.95 - ₹31.71 | -60.0% | EBITDA: ₹8.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹28.83 | ₹23.06 - ₹34.60 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹21.62 | ₹19.46 - ₹23.78 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹32.14 | ₹28.93 - ₹35.35 | -55.4% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹36.03 | ₹32.43 - ₹39.63 | -50.0% | ROE: 6.5%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹43.80 | ₹39.42 - ₹48.18 | -39.2% | EPS: ₹2.08, BVPS: ₹41.00 |
BROOKS Intrinsic Value vs Market Price — All Valuation Models
Brooks Laboratories fair value range ₹22–₹82 vs current market price ₹72.07 across 9 valuation models. Analyse BROOKS shareholding pattern to track promoter, FII and institutional holdings.
BROOKS Intrinsic Value Analysis — Undervalued or Overvalued?
Brooks Laboratories median intrinsic value ₹36.03, current price ₹72.07 — Trading Above Calculated Value by 50.0%, margin of safety -100.0%.
What is the intrinsic value of BROOKS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Brooks Laboratories (BROOKS) is ₹36.03 (median value). With the current market price of ₹72.07, this represents a -50.0% variance from our estimated fair value.
The valuation range spans from ₹21.62 to ₹82.00, indicating ₹21.62 - ₹82.00.
Is BROOKS undervalued or overvalued?
Based on our multi-method analysis, Brooks Laboratories (BROOKS) appears to be trading above calculated value by approximately 50.0%.
BROOKS Financial Health — Key Ratios vs Industry Benchmarks
Brooks Laboratories financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 9.25 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 6.5% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 3.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.59x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
BROOKS Cash Flow Quality — Operating & Free Cash Flow
Brooks Laboratories operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹3 Cr | ₹-20 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹-10 Cr | ₹-10 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-15 Cr | ₹-15 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-37 Cr | ₹-50 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹5 Cr | ₹3 Cr | Positive Free Cash Flow | 7/10 |